Novo Nordisk: Wegovy Price Cut to Boost India Obesity Therapy 5-7x
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
Category : Search result: semaglutide cost
Generic Semaglutide to Create Rs 50,000 Cr Market
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Generic Semaglutide to Create Rs 50bn+ Revenue Opportunity
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
Semaglutide Patent Expiry Creates Rs 50,000 Cr Opportunity
The patent expiry of Novo Nordisk's blockbuster drug semaglutide (Ozempic, Wegovy) opens a massive Rs 50,000+ crore market for Indian generic drugmakers, a new report reveals.
Heart Protection from Semaglutide: Key Findings for India
New data shows semaglutide reduces major heart events by 20%, independent of weight loss. This breakthrough offers new hope for India's early-onset heart disease patients. Learn more.
Weight-loss drugs poised for takeoff, cancer care expands in 2026
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
Indian Pharma Firms Eye Licensing Deals for Obesity Drugs
As patents expire, Indian drugmakers like Lupin and Ajanta Pharma are forging licensing and distribution deals for GLP-1 obesity drugs. The market is set for explosive growth. Explore the key partnerships and market dynamics.
Subhash Bridge restoration cost Rs 110 crore, sparks debate
Ahmedabad Municipal Corporation's Rs 110 crore plan to restore Subhash Bridge is more expensive than building several new flyovers. Get the full details and cost comparison here.
Ajanta Pharma's Semaglutide Deal Boosts Growth Prospects
Ajanta Pharma partners with Biocon to market weight-loss drug semaglutide in 26 markets. Deal expected to add ₹200 crore sales by FY28, enhancing its branded generics focus. Read more.
Obesity Drug Market in India Grows 10-Fold in 5 Years
India's anti-obesity market, now valued at over Rs 1,000 crore, is poised for explosive growth with new drugs and generics. Discover how AI and GLP-1 therapies are transforming healthcare.
Ajanta Pharma & Biocon Partner for Generic Weight Loss Drug
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
FDA Approves Daily Wegovy Pill for Weight Loss
US FDA approves Novo Nordisk's daily Wegovy pill, an oral alternative to injections. Priced from $149, it offers 14% average weight loss. Details on cost, side effects, and how it compares to rivals.
GLP-1 Drugs Show Benefits Beyond Weight Loss
New research reveals GLP-1 drugs like semaglutide offer significant heart, liver, and kidney benefits, transforming treatment for obesity-related conditions. Discover the full scope of their impact.
Emcure Enters Obesity Market with Novo Nordisk's Semaglutide
Emcure Pharmaceuticals launches Poviztra, a weekly semaglutide injection for weight loss, in partnership with Novo Nordisk. Priced from ₹2,200 per week, it targets India's massive obesity market.
Bangladesh Beats India to Export Weight-Loss Drugs to Emerging Markets
Bangladesh's pharma firms have a 2-year head start over Indian giants like Dr Reddy's in exporting generic semaglutide. Delhi HC allows exports, but domestic sales wait until 2026. Explore the competitive landscape.
Court Rejects Ozempic Patent Extension, Boosts Generic Drug Access
Delhi High Court rejects Novo Nordisk's patent plea on semaglutide (Ozempic/Wegovy), preventing 'evergreening'. A win for affordable generics in India, but raises concerns over non-clinical misuse of weight-loss drugs. Read more.
India-Russia Summit: Key Outcomes & UPSC Insights
India & Russia sign 16 pacts, chart roadmap till 2030. Key takeaways on labour mobility, trade, defence & nuclear energy. Essential analysis for UPSC aspirants on bilateral ties, repo rate, labour codes & more.
Delhi HC sides with Dr Reddy's in semaglutide patent case
Delhi High Court rejects Novo Nordisk's plea for interim injunction against Dr Reddy's Labs over semaglutide. Court cites 'evergreening', allows DRL to export. Key ruling for diabetes drug market.
India's Drug Patent Wars: Need for Special Courts?
A recent Delhi High Court order in the Novo Nordisk vs Dr Reddy's case highlights the complexities of Indian patent litigation. We examine the system's challenges and the push for specialized IP courts.
WHO issues first global guidelines for GLP-1 obesity drugs
WHO releases its first global guideline on GLP-1 therapies for obesity, recommending drugs like semaglutide for adults with a BMI over 30. Learn about the impact, safety, and who can benefit.
Dr Reddy's Wins Delhi HC Nod to Export Semaglutide
Delhi High Court permits Dr Reddy's to export generic semaglutide, a major win for Indian drugmakers eyeing the booming anti-obesity market. Read the full analysis.
Oral Ozempic 2.0: Game-Changer Weight Loss Pills
Novo Nordisk and Eli Lilly develop daily oral weight loss pills with 10-16% average weight loss in trials. Pending FDA approval, these could replace injections.
Master Your SIP Strategy for Long-Term Wealth
Discover how SIPs build wealth through discipline & compounding. Learn to use SIP calculators for precise financial goals like retirement & education. Start planning today!
Flight Cheaper Than Cab in NCR, Viral Post Reveals
A viral social media post shows a Delhi to Leh flight costs ₹1,540, while a Gurugram to Greater Noida cab ride is ₹1,952.61. Discover why cab fares are soaring in NCR.
Gadkari: Delhi-Mumbai Expressway to cut logistics cost
Union Minister Nitin Gadkari announced the Delhi-Mumbai Expressway will soon be completed, drastically reducing logistics costs and boosting tourism and exports for India.
BRS Exposes ₹50,000 Cr Power Scam in Telangana
Senior BRS leader Harish Rao accuses Congress government of massive power sector scam involving inflated costs for new thermal plants. Get the full investigation details.
Ahmedabad Wins Bid for 2030 Commonwealth Games
Ahmedabad officially awarded hosting rights for 2030 Commonwealth Games. India previously spent ₹70,000 crore on 2010 Delhi Games, far exceeding initial estimates. Read more about this major sporting event.
Tesla Model Y: 33% Cost Recovery in 4-5 Years
Tesla enters Indian market with Model Y priced 70% higher than US. Company claims buyers can recover one-third of cost through fuel savings in 4-5 years.
Indian Companies Set for Semaglutide Device Windfall
Shaily Engineering and Gland Pharma positioned to benefit from India's semaglutide gold rush as patent expiry opens market for generic weight-loss drugs. Discover how these companies are preparing.
HP to Cut 6,000 Jobs, Save $1B Annually with AI
HP Inc. announces major restructuring, cutting up to 6,000 jobs by 2028 to save $1 billion annually using AI tools. Profit outlook misses estimates amid rising memory chip costs.
Page 1 of 4